Interstitial Lung Diseases Cohort Study in China

Overview

In this project, the clinical diagnosis of interstitial lung diseases was carried out for the population with suspected interstitial lung diseases selected from the community cohort, and the confirmed patients were included into the existing clinical cohort of interstitial lung diseases, forming an interstitial lung diseases special disease cohort consisting of 3,000 patients and corresponding matched control groups. According to characteristics of interstitial lung disease and the needs of National Key R&D Program of China, this study will formulate unified clinical follow-up strategy to do long-term standardized clinical follow-up in patients with interstitial lung disease. The detailed information for clinical diagnosis and treatment as well as biological samples were collected to identify disease phenotype and build the database and biological sample library for interstitial lung disease cohort study. This study aims to provide evidence for molecular classification, screening and validation of biomarkers as well as precise diagnosis and prevention in patients with interstitial lung disease.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2020

Interventions

  • Other: disease history
    • Clinical progression and prognosis of patients with interstitial lung diseases

Clinical Trial Outcome Measures

Primary Measures

  • Database and biological sample library for Chinese patients with interstitial lung disease
    • Time Frame: up to 4 years
    • Data analyses will be mainly descriptive.

Participating in This Clinical Trial

Inclusion Criteria

  • Physician diagnosed IPF during the last 3 months based upon ATS/ERS/JRS/ALAT guidelines 2011
  • Agree to sign the informed consent

Exclusion Criteria

  • Lung transplantation expected within the next 6 months

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • China-Japan Friendship Hospital
  • Collaborator
    • First Affiliated Hospital Guangzhou Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dai Huaping, Deputy Director of Center for Respiratory Diseases – China-Japan Friendship Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.